Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

NCT04184518 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped The Cediranib producer laboratory decided to stop the development of this product.

Conditions

Interventions

Sponsor

Grupo Español Multidisciplinar de Melanoma

Collaborators